Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06500273

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Led by Allogene Therapeutics · Updated on 2026-05-06

250

Participants Needed

64

Research Sites

441 weeks

Total Duration

On this page

Sponsors

A

Allogene Therapeutics

Lead Sponsor

F

Foresight Diagnostics, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.

CONDITIONS

Official Title

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with large B-cell lymphoma (LBCL) per WHO 2017 including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, or primary mediastinal B-cell lymphoma confirmed by pathology
  • Completed a full course of standard first line therapy (e.g., R-CHOP, dose-adjusted EPOCH-R, Pola-R-CHP) with no additional therapies
  • Achieved complete response (CR) or partial response (PR) suitable for observation at end of first line therapy based on PET/CT
  • Positive minimal residual disease (MRD) by Foresight CLARITY IUO MRD test powered by PhasED-Seq
  • Adults aged 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate blood, kidney, liver, lung, and heart function
  • Non-hematologic side effects from prior therapy recovered to baseline or are grade 1 or lower
Not Eligible

You will not qualify if you...

  • History of LBCL with central nervous system involvement, transformation from other malignancies, or T-cell/histiocyte rich LBCL
  • Prior treatment with anti-CD19 targeted therapies
  • Received any anti-cancer treatment, including radiation, after PET/CT and/or MRD testing confirming response
  • Active and clinically significant autoimmune disease
  • Active systemic bacterial, fungal, or viral infections requiring treatment
  • History of another primary cancer or bone marrow disorder within 3 years before enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 64 locations

1

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States, 85234

Actively Recruiting

2

Genesis Cancer and Blood Institute

Hot Springs, Arkansas, United States, 71913

Actively Recruiting

3

Alta Bates Summit Medical Center

Berkeley, California, United States, 94704

Actively Recruiting

4

City of Hope

Duarte, California, United States, 91010

Actively Recruiting

5

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Actively Recruiting

6

University of California, Los Angeles

Los Angeles, California, United States, 90095

Actively Recruiting

7

University of California, Davis Comprehensive Cancer Center

Sacramento, California, United States, 91817

Actively Recruiting

8

University of California, San Diego

San Diego, California, United States, 92037

Actively Recruiting

9

University of California, San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

10

Rocky Mountain Cancer Centers

Denver, Colorado, United States, 80218

Actively Recruiting

11

Medical Oncology Hematology Consultants

Newark, Delaware, United States, 19713

Actively Recruiting

12

MedStar Georgetown University Hospital

Washington D.C., District of Columbia, United States, 20007

Actively Recruiting

13

Miami Cancer Institute at Baptist Health, Inc.

Miami, Florida, United States, 33176

Actively Recruiting

14

Advent Health Cancer Institute

Orlando, Florida, United States, 32804

Actively Recruiting

15

Orlando Health Cancer Institute

Orlando, Florida, United States, 32806

Actively Recruiting

16

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Actively Recruiting

17

Augusta University Georgia Cancer Center

Augusta, Georgia, United States, 30912

Actively Recruiting

18

Rush University Medical Center

Chicago, Illinois, United States, 60612

Actively Recruiting

19

IU Simon Comprehensive Cancer Center

Indianapolis, Indiana, United States, 46202

Actively Recruiting

20

Indiana Blood and Marrow Transplantation

Indianapolis, Indiana, United States, 46237

Actively Recruiting

21

The University of Kansas Hospital

Kansas City, Kansas, United States, 66205

Active, Not Recruiting

22

University of Kentucky Medical Center

Lexington, Kentucky, United States, 40536

Actively Recruiting

23

University of Louisville Health Brown Cancer Center

Louisville, Kentucky, United States, 40202

Actively Recruiting

24

Norton Cancer Institute

Louisville, Kentucky, United States, 40207

Actively Recruiting

25

University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States, 21201

Actively Recruiting

26

The Center for Cancer and Blood Disorders

Bethesda, Maryland, United States, 20817

Actively Recruiting

27

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

28

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Actively Recruiting

29

University of Missouri - Ellis Fischel Cancer Center

Columbia, Missouri, United States, 65212

Actively Recruiting

30

MidAmerica Cancer Care

Kansas City, Missouri, United States, 64132

Actively Recruiting

31

Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, United States, 63110

Actively Recruiting

32

Astera Cancer Care

East Brunswick, New Jersey, United States, 08816

Actively Recruiting

33

John Theurer Cancer Center

Hackensack, New Jersey, United States, 07601

Actively Recruiting

34

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States, 08901

Actively Recruiting

35

Columbia University Irving Medical Center and New York-Presbyterian Hospital

New York, New York, United States, 10032

Actively Recruiting

36

University of Rochester Medical Center

Rochester, New York, United States, 14642

Actively Recruiting

37

Novant Health Cancer Institute- Hematology

Charlotte, North Carolina, United States, 28204

Actively Recruiting

38

Duke Blood Cancer Center

Durham, North Carolina, United States, 27705

Actively Recruiting

39

Oncology Hematology Care - Kenwood

Cincinnati, Ohio, United States, 45236

Actively Recruiting

40

University of Cincinnati Medical Center

Cincinnati, Ohio, United States, 45267

Actively Recruiting

41

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

42

Oncology Associates of Oregon

Eugene, Oregon, United States, 97401

Actively Recruiting

43

Oregon Health and Science University

Portland, Oregon, United States, 97239

Actively Recruiting

44

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States, 19111

Actively Recruiting

45

Avera Cancer Institute

Sioux Falls, South Dakota, United States, 57105

Actively Recruiting

46

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

47

Texas Oncology - Central South

Austin, Texas, United States, 78705

Actively Recruiting

48

Texas Oncology - Dallas Fort Worth

Dallas, Texas, United States, 75246

Actively Recruiting

49

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

50

Texas Transplant Institute

San Antonio, Texas, United States, 78229

Actively Recruiting

51

Texas Oncology - Tyler

Tyler, Texas, United States, 75702

Actively Recruiting

52

Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, United States, 84112

Actively Recruiting

53

Intermountain Health LDS Hospital

Salt Lake City, Utah, United States, 84142

Actively Recruiting

54

University of Virginia

Charlottesville, Virginia, United States, 22903

Actively Recruiting

55

Virginia Cancer Specialists

Fairfax, Virginia, United States, 22031

Actively Recruiting

56

Virginia Oncology Associates - Norfolk

Norfolk, Virginia, United States, 23502

Actively Recruiting

57

Swedish Cancer Institute

Seattle, Washington, United States, 98104

Actively Recruiting

58

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Actively Recruiting

59

Arthur JE Child Comprehensive Cancer Centre

Calgary, Alberta, Canada, T2N 5G2

Actively Recruiting

60

Queen Elizabeth II Health Sciences Centre

Halifax, Nova Scotia, Canada, B3H 2Y9

Actively Recruiting

61

Princess Margaret Cancer Centre - University Health Network

Toronto, Ontario, Canada, M5G 1Z5

Actively Recruiting

62

Centre Integre Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont

Montreal, Quebec, Canada, H1T 2M4

Actively Recruiting

63

CHUM - University of Montreal Hospital Centre

Montreal, Quebec, Canada, H2X 0A9

Actively Recruiting

64

Hopital de'L'Enfant-Jesus

Québec, Quebec, Canada, G1R 2J6

Actively Recruiting

Loading map...

Research Team

A

Allogene Therapeutics, Inc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | DecenTrialz